

Original Article

Seasonal Differences in FEV₁ Response to Bronchodilation: A Comparison between Young and Elderly PatientsChing-Lung Liu^{a, b, *}, Chang-Yi Lin^a, Sheng-Hsiung Yang^c^a Division of Chest Medicine, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, ^b Mackay Medicine, Nursing and Management College, Taipei, Taiwan, ^c Division of Chest Medicine, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan

ARTICLE INFO

Article history:

Received 11 March 2016
 Received in revised form
 14 April 2017
 Accepted 10 January 2018
 Available online 14 February 2018

Keywords:

season,
 asthma,
 bronchodilation,
 FEV₁,
 lung function

SUMMARY

Background: The bronchodilation test is used to detect reversible airways obstruction, which is important for diagnosing asthma. Since asthma activity is influenced by seasons, with higher activity in the spring and fall, this study aimed to determine if the FEV₁ response to bronchodilation is season-dependent.

Methods: All enrolled asthmatic patients underwent pulmonary function testing. Bronchodilation was assessed by measuring FEV₁ change (Δ FEV₁) before and after inhalation of fenoterol 0.4 mg delivered by metered-dose inhaler with a spacer.

Results: There were 348 adult patients with positive bronchodilator test (Δ FEV₁ > 12% and 200 mL). In the younger population (n = 223 aged < 65 years), the Δ FEV₁ in winter (January–March) was $+331.5 \pm 119.0$ mL (mean \pm SD) and $+337.6 \pm 110.2$ mL in summer (July–September). These were significantly less than the results in the other two seasons (April–June, $+398.9 \pm 149.1$ mL and October–December, $+397.4 \pm 183.3$ mL; $p = 0.015$). In the elderly (n = 125 aged ≥ 65 years), the Δ FEV₁ throughout the four seasons was similar ($p = 0.410$).

Conclusions: In younger adults, the bronchodilator variabilities are low in winter and summer, suggesting lower sensitivity of the test due to decreased asthma activity during these seasons. Bronchodilation in the elderly is not season dependent.

Copyright © 2018, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Flow-volume spirometry is a reproducible and reliable method for assessing lung function. The bronchodilation test is used to detect reversible airways obstruction, which is important for diagnosing asthma.^{1,2} In clinical practice, the recommended spirometric bronchodilation response in adults is an increase of 12% and 200 mL from baseline forced expiratory volume in 1 s (FEV₁).^{3,4} The change in FEV₁ (Δ FEV₁) in response to bronchodilation is related to airway hyper-responsiveness and asthma severity, and can be influenced by many factors like age, sex,^{5,6} and bronchodilating medication and its mode of delivery.^{7,8} Morbidity varies with

seasons and is relatively low during summer and winter.^{9,10} The severity of clinical symptoms correlates with the degree of airway hyper-responsiveness. However, if the bronchodilation response is season-dependent remains unknown.

Asthma-related morbidity in children has been predominately linked to allergen exposure and seasonal sensitization. Atopy, however, is uncommon in the elderly with asthma. Whether this relationship of seasonal variation persists in the older population is unknown. Thus, this study aimed to evaluate the effects of seasonal differences on FEV₁ changes in response to bronchodilation in patients with positive bronchodilator test. The results were also compared between the younger and elderly populations.

2. Materials and methods

2.1. Subjects and study design

A total of 2781 patients underwent pulmonary function measurements with bronchodilator testing in an out-patient setting at a

Abbreviations: Δ FEV₁, difference between FEV₁; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow.

* Corresponding author. Division of Chest Medicine, Department of Internal Medicine, Mackay Memorial Hospital, 92, Sec 2, Chung-Shan North Road, Taipei, Taiwan.

E-mail address: lrphael.tw@yahoo.com.tw (C.-L. Liu).

<https://doi.org/10.1016/j.ijge.2018.01.006>

1873-9598/Copyright © 2018, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

tertiary care medical center in Tamsui, Taiwan, between January 2013 and December 2015. Patients were excluded if they were <20 years of age, had poor performance on pulmonary function testing, or had a peak expiratory flow (PEF) < 40% of predicted. All patients with positive bronchodilator test were included and categorized by month. This study was approved by the Institute Board of MacKay Memorial Hospital (16MMHIS032).

2.2. Pulmonary function tests and bronchodilator test

Pulmonary function measurements were performed according to the American Thoracic Society guidelines.^{11,12} No bronchodilators, either β -adrenergic agonists or theophylline, were administered within 8 h before the start of the study. All of the patients also underwent spirometry and lung volume measurements using the nitrogen wash-out method (Vmax 22; SensorMedics; Yorba Linda, CA) in the hospital. The predicted and percent-predicted values were calculated for FEV₁, FVC, and the FEV₁/FVC ratio using the reference values recommended by Knudson et al.¹³

Bronchodilator reversibility tests were performed using the largest FEV₁ and FVC from the best of three spirometry recordings on a single-breath bellows spirometer.¹¹ The subjects then inhaled 0.4 mg of fenoterol (Berotec; Boehringer Ingelheim) using an MDI under the guidance of a well-trained technician. Spirometry was performed and repeated after a 15–20 min delay. A positive bronchodilator response was defined as improvement of the FEV₁ by > 12% and 200 mL compared to baseline during a single testing session.¹¹ Those with a positive bronchodilator response constituted the study population.

2.3. Statistical analysis

All data were expressed as mean \pm SD. Changes in FEV₁ were expressed as absolute and percent changes from baseline. Different variables for the bronchodilator response (Δ FEV₁ in mL and as percentage) were assessed by multiple logistic regression analysis. Analysis of variance (ANOVA), followed by the Fisher's protected least significant difference post hoc test, was used to compare differences in continuous variables among the different age groups. Statistical significance was set at $p < 0.05$. Differences between groups were tabulated and analyzed using the SPSS software (version 16.0; Chicago, IL).

3. Results

3.1. Population sample

A total of 2781 patients underwent pulmonary function measurements by bronchodilator testing during the study period. The




Fig. 1. Boxplots of bronchodilator responses (Δ FEV₁ in mL) of patients presented by month during the calendar year.

response was positive in 348 individuals (223 between 20 and 65 years of age; 125 aged ≥ 65 years), who constituted the study population. According to the month each occurred during the calendar year, individual increases in Δ FEV₁ (bronchodilator response) were shown (Fig. 1).

There was a trend of seasonal differences in bronchodilation response. The responses significantly increased in April and November. Among the four seasons, no differences were found in the FEV₁ values (ml and % of predicted) and FEV₁/FVC ratio at baseline spirometry (Table 1). However, the Δ FEV₁ significantly increased in spring (April–June, $+363.2 \pm 138.3$ mL) and fall (October–December, $+357.2 \pm 163.9$ mL) than in winter and summer ($p = 0.022$).

In the younger population (age <65 years), there was no significant difference in terms of demographic data or severity of baseline pulmonary function in the four seasons (Table 2). The Δ FEV₁ in winter (January–March) was $+331.5 \pm 119.0$ mL and $+337.6 \pm 110.2$ mL in summer (July–September). Both were significantly less than the results in spring and fall (April–June, $+398.9 \pm 149.1$ mL and October–December, $+397.4 \pm 183.3$ mL, respectively; $p = 0.015$) (Fig. 2).

In elderly population (age ≥ 65 years), there was no significant seasonal difference in baseline pulmonary function (Table 3) and there was only a trend of high Δ FEV₁ in spring, as well as low Δ FEV₁ in winter and summer, but without significant difference ($p = 0.410$) (Fig. 2).

Table 1

Characteristics, baseline values, and bronchodilator response of patients with positive bronchodilator test (n = 348).

Variables	January to March (n = 90)	April to June (n = 98)	July to September (n = 67)	October to December (n = 93)	p^a
Age, yr	57.9 \pm 15.5	58.3 \pm 16.5	57.7 \pm 16.8	56.6 \pm 16.7	0.904
Height, cm	162.0 \pm 8.1	162.8 \pm 6.9	162.3 \pm 8.7	162.2 \pm 8.6	0.922
Weight, kg	69.1 \pm 15.2	68.1 \pm 16.2	69.7 \pm 15.7	68.9 \pm 13.5	0.933
Baseline spirometry					
FVC, %	87.9 \pm 18.2	89.6 \pm 19.5	86.4 \pm 19.4	93.8 \pm 18.6	0.068
FEV ₁ , %	66.0 \pm 18.1	66.1 \pm 17.3	68.9 \pm 18.0	70.1 \pm 17.0	0.306
FEV ₁ /FVC, %	61.2 \pm 13.2	60.5 \pm 13.9	65.3 \pm 12.1	61.6 \pm 13.1	0.116
PEF, %	75.2 \pm 24.3	71.2 \pm 22.9	74.9 \pm 22.6	77.3 \pm 23.1	0.329
FEV ₁ increase after bronchodilator test					
Δ FEV ₁ , ml	312.6 \pm 111.9	363.2 \pm 138.3	320.8 \pm 98.0	357.2 \pm 163.9	0.022
Δ FEV ₁ , %	19.9 \pm 7.4	23.2 \pm 11.8	19.5 \pm 7.3	20.7 \pm 10.0	0.038

Abbreviations: Δ FEV₁, difference between FEV₁; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow.

Data are expressed as mean \pm SD.

^a Comparison of four groups by ANOVA for continuous variables.

Table 2

Characteristics, baseline values, and bronchodilator response of young patients with positive bronchodilator test (n = 223).

Variables	January to March (n = 59)	April to June (n = 61)	July to September (n = 41)	October to December (n = 62)	P ^a
Age, yr	48.9 ± 10.6	47.8 ± 10.8	47.1 ± 12.0	48.3 ± 13.9	0.903
Height, cm	163.3 ± 8.4	163.2 ± 7.1	162.7 ± 9.4	163.5 ± 8.2	0.977
Weight, kg	71.0 ± 15.8	68.4 ± 17.7	73.7 ± 17.3	70.2 ± 14.1	0.440
Baseline spirometry					
FVC, %	86.0 ± 16.3	86.7 ± 13.6	83.9 ± 14.9	94.1 ± 18.1	0.005
FEV ₁ , %	65.7 ± 17.8	63.5 ± 12.0	68.1 ± 16.6	69.5 ± 17.7	0.191
FEV ₁ /FVC, %	63.4 ± 13.3	61.8 ± 13.6	67.5 ± 10.7	61.8 ± 13.5	0.121
PEF, %	78.4 ± 24.9	72.6 ± 18.4	77.8 ± 21.7	78.6 ± 24.2	0.401
FEV ₁ increase after bronchodilator test					
ΔFEV ₁ , ml	331.5 ± 119.0	398.9 ± 149.1	337.6 ± 110.2	397.4 ± 183.3	0.015
ΔFEV ₁ , %	18.4 ± 6.4	23.2 ± 12.2	18.4 ± 7.7	21.1 ± 11.4	0.026

Abbreviations: ΔFEV₁, difference between FEV₁; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow. Data are expressed as mean ± SD.

^a Comparison of four groups by ANOVA for continuous variables.




Fig. 2. Bronchodilator responses (ΔFEV₁ in mL) in each of the four seasons of the year among the young (upper) and elderly patients (lower). Data are presented as mean value for each group; $p = 0.015$, by ANOVA for comparison among the four groups in younger adults; $p = 0.410$, by ANOVA for comparison among the elderly; *post hoc* paired comparison achieved significance is shown.

4. Discussion

This study demonstrates that lung function and bronchodilation response differ with months and seasons in the young adult population. The bronchodilator responses to inhaled fenoterol in winter and summer are significantly decreased in the volume of ΔFEV₁ compared to those in spring and fall. This suggests that seasonal differences are an important determinant for the absolute volume of FEV₁ response to bronchodilation. But in the elderly population, seasonal difference may not significantly influence asthma activity and bronchodilation response.

Asthma in the elderly is a growing clinical problem that affects 6–7% of this age-group, but making the distinction between asthma and chronic obstructive pulmonary disease more

difficult as patients get older.^{14,15} This difficulty is due to several factors: the confounding role of smoking and the physiologic effects of aging on the airways, which renders airway obstruction more resistant to bronchodilation.¹⁶ Elderly asthmatics can be arbitrarily divided on clinical grounds into two groups: “aging asthmatics”, or those with asthma since childhood or adolescence, and “late-onset asthmatics”, who may present following an infective episode. Hence, it may be hypothesized that aging asthmatics may have season-dependent asthma activity and bronchodilator response, whereas late-onset asthmatics do not have season-dependent response. These can partly explain the current results that bronchodilator response in the elderly is not significantly season-dependent as in the younger population.

Table 3
Characteristics, baseline values, and bronchodilator response of elderly patients with positive bronchodilator test (n = 125).

Variables	January to March (n = 31)	April to June (n = 37)	July to September (n = 26)	October to December (n = 31)	P ^a
Age, yr	75.1 ± 5.9	75.5 ± 6.9	74.5 ± 6.2	73.2 ± 5.6	0.447
Height, cm	159.5 ± 6.9	162.1 ± 6.4	161.6 ± 7.7	159.7 ± 8.9	0.406
Weight, kg	65.4 ± 13.3	67.7 ± 13.6	63.3 ± 10.2	66.3 ± 12.2	0.585
Baseline spirometry					
FVC, %	91.6 ± 21.2	94.4 ± 26.1	90.4 ± 24.6	93.2 ± 19.8	0.913
FEV ₁ , %	66.6 ± 19.0	70.4 ± 23.3	70.1 ± 20.3	71.2 ± 15.8	0.814
FEV ₁ /FVC, %	56.9 ± 12.1	58.4 ± 14.4	62.0 ± 13.7	61.3 ± 12.5	0.400
PEF, %	69.0 ± 22.0	68.9 ± 29.0	69.8 ± 23.6	74.8 ± 20.9	0.743
FEV ₁ increase after bronchodilator test					
ΔFEV ₁ , ml	276.5 ± 87.9	304.3 ± 93.4	294.2 ± 68.9	276.8 ± 63.5	0.410
ΔFEV ₁ , %	22.7 ± 8.4	23.3 ± 11.2	21.2 ± 6.4	19.9 ± 6.6	0.373

Abbreviations: ΔFEV₁, difference between FEV₁; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow. Data are expressed as mean ± SD.

^a Comparison of four groups by ANOVA for continuous variables.

It is well known that asthma morbidity is season-dependent.¹⁷ The highest number of emergency department visits for asthma occurs in the fall or winter, and the fewest are in summer.⁹ The seasonal variability in asthma activity is likely related to seasonal changes in the prevalence of asthma triggers, which include exposure to allergens, air pollutants, and viral infections.^{18,19} None of these peak in Taiwan during summer.²⁰ The concentration of major air pollutants like nitrogen oxides and sulfur dioxide are also lower in Taiwan during summer compared to any other season.^{20,21} Infection rates from respiratory viruses such as respiratory syncytial virus and influenza are lowest in summer. High or low temperature in summer or winter does not increase asthma activity, but the change in temperature in spring and fall does.

In this study, the study hospital is located at the north of Taiwan (Tamsui), where the winter is wet and cold. Nonetheless, the relative hot or cold temperature does not influence asthma activity or bronchodilator response. Thus, the relative absence of asthma triggers during summer and winter produces less asthma activity during these seasons and consequently, lower sensitivity of bronchodilation testing.

The seasonal variability in the sensitivity of exercise testing correlates well with the seasonal variability of asthma activity. The proportion of positive methacholine challenge test shows significant seasonal trend, significantly higher in winter and in spring than in summer.^{22,23} Therefore, air pollution and viral infections may well influence bronchial hyper-reactivity (BHR) seasonally and along with allergens, may contribute to seasonal asthma morbidity and mortality peaks. To date, this is the first study to demonstrate a significant seasonal trend in bronchodilator test, especially in the young population, but not in the elderly population.

Some limitations were present in the study. As a retrospective study, we could not record additional clinical data from the patients, such as symptoms, exacerbation events, specific IgE measurements, or medications. However, the present study focused on seasonal effects in bronchodilator responsiveness. As lung function tests were performed only during the time of stable disease, the influence of exacerbation on lung functions would be minimal. Another limitation was the variation in time between inhalation and the second spirometry. The second measurements were generally made 15–20 min after inhalation. These variations might affect the values obtained for bronchodilation response. Nonetheless, the data are robust enough to demonstrate the essentially equivalent lung functions and bronchodilation responses with aging.^{24,25}

In conclusion, this study demonstrates that age is an important determinant for lung function and bronchodilation response. In younger adults, the bronchodilator test results in winter and summer are less than in spring and fall, reflecting a lower

sensitivity of the test during these seasons due to decreased asthma activity. In contrast, bronchodilation in elderly is not season-dependent.

Acknowledgement

The authors thank Mrs. Yu-Siou Huang for performing the pulmonary function tests.

References

- Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005;26:948–968.
- Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention*; 2017. Available at: <http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/>. Accessed April 14, 2017.
- American Thoracic Society. ATS standardization of spirometry: 1994 update. *Am J Respir Crit Care Med*. 1994;152:1107–1136.
- Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2001;163:1256–1276.
- Dompeling E, van Schayck CP, Molema J, et al. A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of pre-bronchodilator FEV₁. *Eur Respir J*. 1992;5:975–981.
- Dales RE, Spitzer WO, Tousignant P, et al. Clinical interpretation of airway response to a bronchodilator: Epidemiologic considerations. *Am Rev Respir Dis*. 1988;138:317–320.
- Newman SP, Weisz AW, Talaei N, et al. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. *Thorax*. 1991;46:712–716.
- Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. *Thorax*. 1996;51:835–840.
- Silverman RA, Stevenson L, Hastings HM. Age-related seasonal patterns of emergency department visits for acute asthma in an urban environment. *Ann Emerg Med*. 2003;42:577–586.
- Rossi OV, Kinnula VL, Tienari J, et al. Association of severe asthma attacks with weather, pollen, and air pollutants. *Thorax*. 1993;48:244–248.
- American Thoracic Society. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med*. 1995;152:1107–1136.
- American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. *Am Rev Respir Dis*. 1991;144:1202–1218.
- Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow-volume curve with growth and aging. *Am Rev Respir Dis*. 1983;127:725–734.
- Burrows B, Barbee R, Cline M, et al. Characteristics of asthma among elderly adults in a sample of the general population. *Chest*. 1991;100:935–942.
- Kaczmarczyk K, Wiszomirska I, Magiera A, et al. Changes in lung function and anthropometric parameters post training in older women. *J Gerontol*. 2015;9:123–125.
- Inal-Ince D, Savci S, Saglam M, et al. Predictors of physical inactivity in elderly patients with chronic obstructive pulmonary disease. *J Gerontol*. 2013;8:193–196.
- Weiss KB. Seasonal trends in US asthma hospitalizations and mortality. *JAMA*. 1990;263:2323–2328.
- Rossi OV, Kinnula VL, Tienari J, et al. Association of severe asthma attacks with weather, pollen, and air pollutants. *Thorax*. 1993;48:244–248.
- D'Amato G, Liccardi G, D'Amato M, et al. Outdoor air pollution, climatic changes and allergic bronchial asthma. *Eur Respir J*. 2002;20:763–773.

20. Yeh KW, Chang CJ, Hung JL. The association of seasonal variation of asthma hospitalization with air pollution among children in Taiwan. *Asian Pac J Allergy Immunol.* 2011;29:34–41.
21. Han YY, Lee YL, Guo YL. Indoor environmental risk factors and seasonal variation of childhood asthma. *Pediatr Allergy Immunol.* 2009;20:748–756.
22. Fruchter O, Yigla M. Seasonal variability of the methacholine challenge test. *J Asthma.* 2009;46:951–954.
23. Sposato B, Scalese M, Pammoli A, et al. Seasons can influence the results of the methacholine challenge test. *Ann Thorac Med.* 2012;7:61–68.
24. Liu CL, Wu CL, Lu YT. Effects of age on FEV₁ response to bronchodilation. *Int J Gerontol.* 2009;3:149–155.
25. Liu CL, Lu YT. Bronchodilatation effects of a small volume spacer used with a metered-dose inhaler. *J Asthma.* 2009;46:637–641.